Obsessive - Compulsive DisorderFARNCT07912177
Family Accommodation Reduction in Adult Obsessive Compulsive Disorder
A study testing Family Accommodation Reduction and Family Psychoeducation in people with Obsessive - Compulsive Disorder and Family Accommodation, run by Karen Rowa at 2 sites in Canada.
Trial summary
The goal of this clinical trial is to learn if offering a Family Accommodation Reduction (FAR) intervention to family members before OCD patients start CBT can improve CBT outcomes. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Obsessive - Compulsive Disorder, Family Accommodation, OCD
- What is being tested?
- Family Accommodation Reduction and Family Psychoeducation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 480 participants
- Where
- 2 sitesCanada
- Study dates
- 10 Sep 2026to 31 Mar 2032
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with OCD:
- 18-65 years
- primary diagnosis of OCD based on DSM-5
- clinically significant obsessive compulsive symptoms (Yale-Brown Obsessive-Compulsive Scale, 2nd edition > 20)
- if on medications for OCD, must be on a stable (at least 6 weeks) prior to the initiation of the study.
- Family members:
Show all 12Show fewer
- 18-65 years old
- has been sharing accommodations with the patient for a minimum of 9 of the last 12 months
- is a parent, spouse, partner, sibling or an adult child of the patient with OCD
- reports at least moderate Family Accommodation levels based on the Family Accommodation Scale for Obsessive-Compulsive Disorder-Self-Rated Version score>14 (Pinto et al., 2013)
- no known current diagnosis of schizophrenia, bipolar disorder or organic brain illness (which will be asked about in the Family Member Phone Screen)
- has access to a Zoom capable device, a stable internet connection, and a private location to attend sessions.
Who cannot join
- Patients with OCD:
- severe mood disorder, schizophrenia/psychotic disorders or significant substance abuse/dependence
- suspected organic pathology
- full course of CBT for OCD within the past year (i.e., more than 8 sessions)
- an active comorbid medical condition that may require urgent intervention during the treatment.
- Participants incapable of providing informed consent will be excluded.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Canada2 sites
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, L8N 3K7
Sunnybrook Health Sciences Centre
North York, Ontario, M4N 3M5
About this study
Official title: Family Accommodation Reduction in Adult Obsessive Compulsive Disorder: A Randomized Controlled Trial
The goal of this clinical trial is to learn if offering a Family Accommodation Reduction (FAR) intervention to family members before OCD patients start CBT can improve CBT outcomes. The current study will offer 6 sessions of Family Accommodation Reduction (FAR) or OCD psychoeducation for the family member before the person with OCD receives 12 sessions of group CBT (GCBT).
The main questions it aims to answer are:
Read more
- Is the addition of FAR associated with superior outcomes at the end of standard GCBT and at 3 month follow up in comparison to our control group?
- Is reduction in Family Accommodation a mechanism by which FAR is impacting the outcomes of GCBT?
Researchers will compare CBT outcomes between people whose family member received the FAR intervention versus psychoeducation and see if any benefits last at a 3-month follow-up.
Participating Family Members will:
- receive 6 weeks of FAR or Psychoeducation
- answer online questionnaires at several time points throughout the study about OCD symptom severity, quality of life, and level of functioning for the person with OCD.
Participating Patients will:
- complete 12 weeks of CBT for OCD
- answer online questionnaires at several time points throughout the study about OCD symptom severity, quality of life, and level of functioning.
Read the detailed description
Obsessive compulsive disorder (OCD) is a common and disabling disorder. Effective treatments include medication and cognitive behavioural therapy (CBT), but many people continue to experience symptoms. Thus, it is important to consider ways to improve treatment outcomes for people with OCD. A promising option is to address family accommodation. Family accommodation, a common but problematic behavior, occurs when family members participate in OCD rituals, change their expectations of their loved one, or modify their own behaviours to make their loved one with OCD feel better. Family accommodation is related to worse OCD symptoms and outcomes in CBT. To address this, our team created a 6-session skill-training intervention that helps family members reduce accommodation in a gradual and manageable way. In a pilot study, we offered this intervention to family members independent of CBT for the person with OCD. Family members found this intervention helpful, and it resulted in large reductions in accommodation. The next step is to see if offering this intervention to family members before patients start CBT can improve CBT outcomes. The current study will offer 6 sessions of Family Accommodation Reduction (FAR) or OCD psychoeducation for the family member before the person with OCD receives 12 sessions of group CBT. We will compare CBT outcomes between people whose family member received the FAR intervention versus psychoeducation and see if any benefits last at a 3-month follow-up. We predict that patients whose family member receives FAR will do better in CBT than patients whose family receives psychoeducation. We will measure OCD symptom severity, quality of life, and level of functioning for the person with OCD. The results of this study could provide a valuable, transferable option to augment CBT outcomes for people with OCD.
- Conditions
- Obsessive - Compulsive Disorder, Family Accommodation, OCD, CBT, Psychoeducation
- Being tested
- Family Accommodation Reduction, Family Psychoeducation
- Keywords
- Obsessive Compulsive Disorder, Family Accommodation, Intervention, CBT, Psychoeducation
- Medical subject headings
- Compulsive Personality Disorder, Obsessive-Compulsive Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Family Accommodation ReductionBehavioural
6 week Family Accommodation Reduction Intervention
Family PsychoeducationBehavioural
6 week Family Psychoeducation program for OCD
| Study group | Role | What they receive |
|---|---|---|
| Family Accommodation Reduction | Active comparator | Family member randomized to this condition will receive 6 weeks of a Family Accommodation Reduction intervention Receives: Behavioral: Family Accommodation Reduction |
| Family Psychoeducation | Active comparator | Family member randomized to this condition will receive 6 weeks of Family Psychoeducation for OCD Receives: Behavioral: Family Psychoeducation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in OCD Symptom Severity from Baseline to 3-Months Post-Treatment (Patient Self-Report)
OCD symptom severity is measured by the self-report Yale-Brown Obsessive-Compulsive Scale, Second Edition (Y-BOCS-II; Storch et al., 2010). The Y-BOCS-II has 10 items pertaining to obsessions and compulsions rated on a Likert scale. Scores range from 0 to 40 with higher scores indicating increased symptom severity.
Measured: Baseline to 3-Months Post-Treatment
Change in Quality of Life from Baseline to 3-Months Post-Treatment (Patient Self-Report)
Quality of life is measured by the Illness Intrusiveness Rating Scale (IIRS; Devins, 1994). The IIRS is a 13-item self-report measure of the degree to which symptoms interfere with important life domains (e.g., work, family relationships). Total scores range from 13 (minimum intrusiveness) to 91 (extreme intrusiveness).
Measured: Baseline to 3-Months Post-Treatment
Change in Functional Impairment from Baseline to 3-Months Post-Treatment (Patient Self-Report)
Functional Impairment is measured by:
- The Sheehan Disability Scale (SDS; Sheehan et al., 1983). The SDS is a brief measure of disability and functional impairment due to psychiatric or medical symptoms focused on work, social life/leisure activities, and family life/home responsibilities. Scores range from 0 (unimpaired) to 30 (highly impaired).
- The Family Functioning Scale (FFS; Stewart et al., 2017). The FFS is a self-report scale of how much family impairment arises from OCD symptoms. Scores range from 0 to 63 with higher scores indicating increased family impairment.
Measured: Baseline to 3-Months Post-Treatment
Secondary outcomes (11)
Change in Family Accommodation from Baseline to 3-Months Post-Treatment (Family Member Self- Report)
Family Accommodation is measured by the Family Accommodation Scale for Obsessive-Compulsive Disorder - Self-Rated Version (FAS-SR, Pinto et al., 2013). The FAS-SR is a 19-item self-report measure that gathers information about the degree to which family members participate in accommodating behaviours. Scores range from 0 to 76 with higher scores indicating more family accommodation.
Measured: Baseline to 3-Months Post-Treatment
Change in Family Accommodation from Baseline to 3-Months Post-Treatment (Patient Self- Report)
Family Accommodation is measured by the Family Accommodation Scale for Obsessive-Compulsive Disorder - Patient Version (FAS-PV; Wu et al., 2016) is a 19-item self-report measure that gathers information about the degree to which an OCD patient's family member participates in accommodating behaviours. Scores range from 0 to 76 with higher scores indicating more family accommodation.
Measured: Baseline to 3-Months Post-Treatment
Change in OCD Symptom Severity from Baseline to 3-Months Post-Treatment (Family Member Self-Report)
OCD symptom severity is measured by the self-report Yale-Brown Obsessive-Compulsive Scale, Second Edition (Y-BOCS-II; Storch et al., 2010). This will be administered to family members as well given the tendency for OCD symptoms to cluster within families. The Y-BOCS-II has 10 items pertaining to obsessions and compulsions rated on a Likert scale. Scores range from 0 to 40 with higher scores indicating increased symptom severity.
Measured: Baseline to 3-Months Post-Treatment
Change in Severity of Depression, Anxiety, and Stress from Baseline to 3-Months Post-Treatment (Patient Self-Report)
The Depression Anxiety Stress Scale-21 (DASS-21; Lovibond \& Lovibond, 1995) is a 21-item self-report measure designed to assess the severity of depression, anxiety, and stress symptoms. Scores range from 0 to 63 on each of the subscales (Depression, Anxiety, and Stress), with higher scores indicating increased symptom severity.
Measured: Baseline to 3-Months Post-Treatment
Change in Severity of Depression, Anxiety, and Stress from Baseline to 3-Months Post-Treatment (Family Member Self-Report)
The Depression Anxiety Stress Scale-21 (DASS-21; Lovibond \& Lovibond, 1995) is a 21-item self-report measure designed to assess the severity of depression, anxiety, and stress symptoms. Scores range from 0 to 63 on each of the subscales (Depression, Anxiety, and Stress), with higher scores indicating increased symptom severity.
Measured: Baseline to 3-Months Post-Treatment
Change in Quality of Life from Baseline to 3-Months Post-Treatment (Family Member Self-Report)
Quality of life is measured by the Illness Intrusiveness Rating Scale (IIRS; Devins, 1994). The IIRS is a 13-item self-report measure of the degree to which symptoms interfere with important life domains (e.g., work, family relationships). Total scores range from 13 (minimum intrusiveness) to 91 (extreme intrusiveness).
Measured: Baseline to 3-Months Post-Treatment
Change in Functional Impairment from Baseline to 3-Months Post-Treatment (Family Member Self-Report)
Functional Impairment is measured by the Sheehan Disability Scale (SDS; Sheehan et al., 1983). The SDS is a brief measure of disability and functional impairment due to psychiatric or medical symptoms focused on work, social life/leisure activities, and family life/home responsibilities. Scores range from 0 (unimpaired) to 30 (highly impaired).
Measured: Baseline to 3-Months Post-Treatment
Change in Family Functional Impairment from Baseline to 3-Months Post-Treatment (Family Member Self-Report)
Family Functional Impairment is measured by the Family Functioning Scale (FFS; Stewart et al., 2017). The FFS is a self-report scale of how much family impairment arises from OCD. Scores range from 0 to 63 with higher scores indicating increased family impairment.
Measured: Baseline to 3-Months Post-Treatment
Change in Emotional Expression from Baseline to 3-Months Post-Treatment (Family Member Self-Report)
Emotional expression is measured by the Family Questionnaire (FQ; Wiedemann, Rayki, Feinstein, \& Hahlweg, 2002). The FQ is a 20 items self-report measure of criticism and emotional overinvolvement. Scores range from 20 to 80, with higher scores indicating greater levels of expressed emotion.
Measured: Baseline to 3-Months Post-Treatment
Change in Perception of Expressed Emotion from Baseline to 3-Months Post-Treatment (Patient Self-Report)
Perception of Expressed Emotion is measured by the Brief Dyadic Scale of Expressed Emotion (BDSEE; Medina-Pradas et al., 2011). The BDSEE is a 14 item scale assessing patients' perceptions of loved ones' expressed emotions on two components: Critical comments and Emotional overinvolvement. Scores range from 0 to 140 with higher scores indicating higher levels of criticism, hostility, and emotional overinvolvement within close relationships.
Measured: Baseline to 3-Months Post-Treatment
Change in Obsessive-Compulsive Characteristics from Baseline to 3-Months Post-Treatment (Patient Self-Report)
Obsessive-Compulsive Characteristics are measured by the Obsessive-Compulsive Trait Core Dimensions Questionnaire (OC-TCDQ; Summerfeldt et al., 2014). the OC-TCDQ is a 20- item self-report measure scored across two dimensions: Harm Avoidance (HA) and Incompleteness (INC). Scores range from 20 to 100 with higher scores indicating stronger motivational tendencies toward harm avoidance and/or incompleteness.
Measured: Baseline to 3-Months Post-Treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Nov 2026
- Study start10 Sep 2026
- Primary completion30 Sep 2031 (estimated)
- Study completion31 Mar 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obsessive - Compulsive DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 480 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Karen Rowa
- Sponsor type
- University, hospital or other
- Collaborators
- McMaster University, Sunnybrook Health Sciences Centre, St. Joseph's Healthcare Hamilton
- Responsible party
- Sponsor-investigator, Karen Rowa, St. Joseph's Healthcare Hamilton
- Investigators
- Neil Rector, PhD, C.Psych., Principal investigator, Sunnybrook Health Sciences Centre
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07912177
- Sponsor's protocol ID
- 5839
- Other IDs
- 189456
- Acronym
- FAR
- Status last verified
- Oct 2026
- First submitted
- 27 Oct 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The data collected is on vulnerable populations with mental health difficulties.
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Family Accommodation Reduction in Adult Obsessive Compulsive Disorder: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07912177
- Acronym / sponsor ID
- FAR / 5839
- Conditions
- Obsessive - Compulsive Disorder, Family Accommodation, OCD, CBT, Psychoeducation
- Keywords
- Obsessive Compulsive Disorder, Family Accommodation, Intervention, CBT, Psychoeducation
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 480 participants (estimated)
- Lead sponsor
- Karen RowaUniversity, hospital or other
- Collaborators
- McMaster University, Sunnybrook Health Sciences Centre, St. Joseph's Healthcare Hamilton
- Study start
- 10 Sep 2026 (actual)
- Primary completion
- 30 Sep 2031 (estimated)
- Study completion
- 31 Mar 2032 (estimated)
- First posted
- 3 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if offering a Family Accommodation Reduction (FAR) intervention to family members before OCD patients start CBT can improve CBT outcomes. The current study will offer 6 sessions of Family Accommodation Reduction (FAR) or OCD psychoeducation for the family member before the person with OCD receives 12 sessions of group CBT (GCBT).
The main questions it aims to answer are:
- Is the addition of FAR associated with superior outcomes at the end of standard GCBT and at 3 month follow up in comparison to our control group?
- Is reduction in Family Accommodation a mechanism by which FAR is impacting the outcomes of GCBT?
Researchers will compare CBT outcomes between people whose family member received the FAR intervention versus psychoeducation and see if any benefits last at a 3-month follow-up.
Participating Family Members will:
- receive 6 weeks of FAR or Psychoeducation
- answer online questionnaires at several time points throughout the study about OCD symptom severity, quality of life, and level of functioning for the person with OCD.
Participating Patients will:
- complete 12 weeks of CBT for OCD
- answer online questionnaires at several time points throughout the study about OCD symptom severity, quality of life, and level of functioning.
Detailed description
Obsessive compulsive disorder (OCD) is a common and disabling disorder. Effective treatments include medication and cognitive behavioural therapy (CBT), but many people continue to experience symptoms. Thus, it is important to consider ways to improve treatment outcomes for people with OCD. A promising option is to address family accommodation. Family accommodation, a common but problematic behavior, occurs when family members participate in OCD rituals, change their expectations of their loved one, or modify their own behaviours to make their loved one with OCD feel better. Family accommodation is related to worse OCD symptoms and outcomes in CBT. To address this, our team created a 6-session skill-training intervention that helps family members reduce accommodation in a gradual and manageable way. In a pilot study, we offered this intervention to family members independent of CBT for the person with OCD. Family members found this intervention helpful, and it resulted in large reductions in accommodation. The next step is to see if offering this intervention to family members before patients start CBT can improve CBT outcomes. The current study will offer 6 sessions of Family Accommodation Reduction (FAR) or OCD psychoeducation for the family member before the person with OCD receives 12 sessions of group CBT. We will compare CBT outcomes between people whose family member received the FAR intervention versus psychoeducation and see if any benefits last at a 3-month follow-up. We predict that patients whose family member receives FAR will do better in CBT than patients whose family receives psychoeducation. We will measure OCD symptom severity, quality of life, and level of functioning for the person with OCD. The results of this study could provide a valuable, transferable option to augment CBT outcomes for people with OCD.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Family Accommodation Reduction | Active comparator | Behavioral: Family Accommodation ReductionFamily member randomized to this condition will receive 6 weeks of a Family Accommodation Reduction intervention |
| Family Psychoeducation | Active comparator | Behavioral: Family PsychoeducationFamily member randomized to this condition will receive 6 weeks of Family Psychoeducation for OCD |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- 18-65 years
- primary diagnosis of OCD based on DSM-5
- clinically significant obsessive compulsive symptoms (Yale-Brown Obsessive-Compulsive Scale, 2nd edition > 20)
- if on medications for OCD, must be on a stable (at least 6 weeks) prior to the initiation of the study.
- 18-65 years old
Key exclusion criteria (6 listed)
- severe mood disorder, schizophrenia/psychotic disorders or significant substance abuse/dependence
- suspected organic pathology
- full course of CBT for OCD within the past year (i.e., more than 8 sessions)
- an active comorbid medical condition that may require urgent intervention during the treatment.
- Participants incapable of providing informed consent will be excluded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Family Accommodation Reduction6 week Family Accommodation Reduction Intervention | Behavioural | Family Accommodation Reduction |
| Family Psychoeducation6 week Family Psychoeducation program for OCD | Behavioural | Family Psychoeducation |
Primary outcome
Change in OCD Symptom Severity from Baseline to 3-Months Post-Treatment (Patient Self-Report)
Time frame: Baseline to 3-Months Post-Treatment
OCD symptom severity is measured by the self-report Yale-Brown Obsessive-Compulsive Scale, Second Edition (Y-BOCS-II; Storch et al., 2010). The Y-BOCS-II has 10 items pertaining to obsessions and compulsions rated on a Likert scale. Scores range from 0 to 40 with higher scores indicating increased symptom severity.
Change in Quality of Life from Baseline to 3-Months Post-Treatment (Patient Self-Report)
Time frame: Baseline to 3-Months Post-Treatment
Quality of life is measured by the Illness Intrusiveness Rating Scale (IIRS; Devins, 1994). The IIRS is a 13-item self-report measure of the degree to which symptoms interfere with important life domains (e.g., work, family relationships). Total scores range from 13 (minimum intrusiveness) to 91 (extreme intrusiveness).
Change in Functional Impairment from Baseline to 3-Months Post-Treatment (Patient Self-Report)
Time frame: Baseline to 3-Months Post-Treatment
Functional Impairment is measured by: 1. The Sheehan Disability Scale (SDS; Sheehan et al., 1983). The SDS is a brief measure of disability and functional impairment due to psychiatric or medical symptoms focused on work, social life/leisure activities, and family life/home responsibilities. Scores range from 0 (unimpaired) to 30 (highly impaired). 2. The Family Functioning Scale (FFS; Stewart et al., 2017). The FFS is a self-report scale of how much family impairment arises from OCD symptoms. Scores range from 0 to 63 with higher scores indicating increased family impairment.
11 secondary outcomes
Change in Family Accommodation from Baseline to 3-Months Post-Treatment (Family Member Self- Report)
Time frame: Baseline to 3-Months Post-Treatment
Change in Family Accommodation from Baseline to 3-Months Post-Treatment (Patient Self- Report)
Time frame: Baseline to 3-Months Post-Treatment
Change in OCD Symptom Severity from Baseline to 3-Months Post-Treatment (Family Member Self-Report)
Time frame: Baseline to 3-Months Post-Treatment
Change in Severity of Depression, Anxiety, and Stress from Baseline to 3-Months Post-Treatment (Patient Self-Report)
Time frame: Baseline to 3-Months Post-Treatment
Change in Severity of Depression, Anxiety, and Stress from Baseline to 3-Months Post-Treatment (Family Member Self-Report)
Time frame: Baseline to 3-Months Post-Treatment
Change in Quality of Life from Baseline to 3-Months Post-Treatment (Family Member Self-Report)
Time frame: Baseline to 3-Months Post-Treatment
Change in Functional Impairment from Baseline to 3-Months Post-Treatment (Family Member Self-Report)
Time frame: Baseline to 3-Months Post-Treatment
Change in Family Functional Impairment from Baseline to 3-Months Post-Treatment (Family Member Self-Report)
Time frame: Baseline to 3-Months Post-Treatment
Change in Emotional Expression from Baseline to 3-Months Post-Treatment (Family Member Self-Report)
Time frame: Baseline to 3-Months Post-Treatment
Change in Perception of Expressed Emotion from Baseline to 3-Months Post-Treatment (Patient Self-Report)
Time frame: Baseline to 3-Months Post-Treatment
Change in Obsessive-Compulsive Characteristics from Baseline to 3-Months Post-Treatment (Patient Self-Report)
Time frame: Baseline to 3-Months Post-Treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Individual participant dataSharing planned: No. The data collected is on vulnerable populations with mental health difficulties.
Related trials for Obsessive - Compulsive Disorder
Not yet recruitingObservational study
Investigation of Obsessive-Compulsive Disorder in Patients With Elbow Epicondylitis
Lateral Epicondylitis, Medial Epicondylitis
Recruiting
Precision Analytic Research Methods in OCD
Obsessive Compulsive Disorder
Recruiting
Focused Ultrasound for Behavioral Health
Depression, Anxiety
Not yet recruiting
Linear Accelerator Radiosurgical Anterior Capsulotomy With Task-based fMRI Identification of PERSonalized and PrEdictiVE Biomarkers of REsponse in Treatment-Refractory Obsessive-Compulsive Disorder (PERSEVERE Trial)
Treatment-refractory Obsessive-compulsive Disorder (trOCD)
Recruiting
tDCS Associated With Symptom Provocation in the Management of Patients With Resistant Obsessive Compulsive Disorder
Obsessive-Compulsive Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Neil Rector, PhD, C.Psych. principal investigator
Sunnybrook Health Sciences Centre
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Family Accommodation Reduction and Family Psychoeducation in people with Obsessive - Compulsive Disorder and Family Accommodation, run by Karen Rowa at 2 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in OCD Symptom Severity from Baseline to 3-Months Post-Treatment (Patient Self-Report) (time frame: Baseline to 3-Months Post-Treatment). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.